Drug
Tipranavir clinical trials
- studies test it
- 34
- open now
- 0
- in phase 3
- 7
- first study started
- 1999
How studies write it
Studies that test it under each name
Name
Brand
Combined with it in one product
Studies by the year they started
34 studies that test it; most in 2003 (9)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 9 |
| 2004 | 1 |
| 2005 | 6 |
| 2006 | 5 |
| 2007 | 7 |
| 2008 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 21
- Phase 2
- 6
- Phase 3
- 7
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 29 · Other 5
Boehringer Ingelheim (29) · Germans Trias i Pujol Hospital (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Yale University (1) · Johns Hopkins University (1)
Often tested with
Tested in the same studies.
Ritonavir (22) · Saquinavir (2) · Darunavir (2) · Efavirenz (2) · Atazanavir (2) · Interferons (1) · Ribavirin (1) · Amprenavir (1)
Studies
Open first, then newest update. How each study uses tipranavir is read from its arms, and is right about nine times in ten.
Testing it · 34
- Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic InsufficiencyCompletedPhase 1Boehringer IngelheimNCT02249442Written as Tipranavir (TPV)
- Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic ImpairmentCompletedPhase 1Boehringer IngelheimNCT02259855Written as Tipranavir
- 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining StudyCompletedPhase 2Boehringer IngelheimNCT00275444Written as Tipranavir
- Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected PatientsCompletedPhase 2Boehringer IngelheimNCT00056641Written as tipranavir
- Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT00537394Written as Tipranavir
- Pharmacokinetic Interactions Between Buprenorphine and Tipranavir/RitonavirCompletedNot applicableYale UniversityNCT00486330Written as Buprenorphine, Tipranavir and ritonavir
- Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 HoursCompletedPhase 4Germans Trias i Pujol HospitalNCT00607958Written as tipranavir/ritonavir (dose reduction)
- Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIVCompletedPhase 1Germans Trias i Pujol HospitalNCT00307502Written as Tipranavir/ ritonavir
- Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy SubjectsCompletedPhase 1Johns Hopkins UniversityNCT00344123Written as Tipranavir/Ritonavir
- Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02257021Written as Tipranavir
- Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male VolunteersCompletedPhase 1Boehringer IngelheimNCT02253862Written as Tipranavir
- Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of RitonavirCompletedPhase 1Boehringer IngelheimNCT02253836Written as Tipranavir
- Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult VolunteersCompletedPhase 1Boehringer IngelheimNCT02253875Written as Tipranavir (TPV)
- Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02253797Written as 14C-Tipranavir
- Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of TipranavirCompletedPhase 1Boehringer IngelheimNCT02251769Written as Tipranavir
- Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02251158Written as Tipranavir oral solution
- Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy SubjectsCompletedPhase 1Boehringer IngelheimNCT02251795Written as Tipranavir
- The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02251119Written as Tipranavir
- Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without TipranavirCompletedPhase 2Boehringer IngelheimNCT02249130Written as Tipranavir (TPV)
- Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02245269Written as Tipranavir
See all 34 studies that test tipranavir →
Given in every arm · 2 — tipranavir is usual care beside what is tested
- Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult VolunteersCompletedPhase 1Boehringer IngelheimNCT02253849Written as Tipranavir
- Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult VolunteersCompletedPhase 1Boehringer IngelheimNCT02251171Written as Tipranavir
Codes
What other systems call tipranavir · ClinicalTrials.gg INT004004
- MeSH (NLM) C107201tipranavirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) ZZT404XD09TIPRANAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 190548Confirmed FDA, Wikidata
- Wikidata Q423404tipranavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C66603TipranavirOne source FDA
- DrugBank DB00932One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C107201 | tipranavir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | ZZT404XD09 | TIPRANAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 190548 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423404 | tipranavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C66603 | Tipranavir | One source FDA |
| DrugBank | DB00932 | — | One source Wikidata |
Also registered as (2r)-3,6-dihydro-6-oxo-2-(2-phenylethyl)-2-propyl-5-((1r)-1-(3-(((5-(trifluoromethyl)-2-pyridinyl)sulfonyl)amino)phenyl)propyl)-2h-pyran-4-yl .beta.-d-glucopyranosiduronic acid (UNII AAY9UHT656), tipranavir c-14 (UNII VU8T5RB4VW) and tipranavir disodium (UNII 9BAN2XG1ZW).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.